Abstract

Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post-hoc analysis to quantify the effect of lebrikizumab vs placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes itch and itch interference on sleep. Approximately two-thirds of the improvement in DLQI experienced by lebrikizumab-treated patients vs placebo-treated patients at Week 16 was mediated by improvement in itch and the interference of itch on sleep.

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author

More From: Clinical and experimental dermatology

Paper Title
Journal
Date
Author

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.